 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- AlbuRx (human albumin) / CSL Behring
FLINDERS ALBUMIN IN THE HOME (FAITH): A FEASIBILITY STUDY () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2854;
HA may provide a logistical and cost effective option to administer albumin in cirrhosis. Larger studies validating our pilot study findings are indicated.
- | AlbuRx (human albumin) / CSL Behring, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
New trial: Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (clinicaltrials.gov) - Jul 3, 2024
P=N/A, N=174, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- | AlbuRx (human albumin) / CSL Behring
Journal: Cerebral O and CO transport in isovolumic haemodilution: Compensation of cerebral delivery of O and maintenance of cerebrovascular reactivity to CO. (Pubmed Central) - Sep 23, 2022
The net cerebral uptake of nitrite (11.6 ± 14.0 nmol/min; P = 0.027) at baseline was abolished following haemodilution (-3.6 ± 17.9 nmol/min; P = 0.54), perhaps underpinning the conservation of CVR (61.7 ± 19.0 vs. 69.0 ± 19.2 mL/min/mmHg; P = 0.23). These findings demonstrate that the cerebrovascular responses to acute anaemia in healthy humans are sufficient to support the maintenance of CVR.
- | AlbuRx (human albumin) / CSL Behring
Journal: Chloride and Other Electrolyte Concentrations in Commonly Available 5% Albumin Products. (Pubmed Central) - Sep 7, 2019
This study is the first to identify and document a statistically significant variability in the chloride concentration of available 5% albumin products. This study has also informed a pilot randomized controlled trial examining the effect of administering high chloride versus low chloride fluids in critically ill patients with sepsis.